Kinnate Biopharma, Inc.
Kinnate Biopharma, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Kinnate Biopharma, Inc..
Kinnate Biopharma, Inc. is a company.
Key people at Kinnate Biopharma, Inc..
Key people at Kinnate Biopharma, Inc..
Kinnate Biopharma Inc. was a clinical-stage precision oncology company developing selective small molecule kinase inhibitors to target genomically defined cancer drivers, aiming to provide effective therapies for patients lacking approved targeted treatments or facing resistance to existing drugs.[1][2][3] Headquartered in San Diego, CA, it focused on cancers with specific genetic alterations like BRAF, NRAS, FGFR2/3, c-MET, and CDK4, serving oncology patients through a pipeline including lead candidate exarafenib (pan-RAF inhibitor) for BRAF-driven solid tumors and NRAS mutant melanoma, plus FGFR inhibitor KIN-3248 and early-stage programs.[1][3] The company emphasized high selectivity, broad genetic coverage, resistance overcoming, and brain penetration to achieve a therapeutic window for lasting clinical responses, but by early 2024, it sold key assets like exarafenib to Pierre Fabre and was acquired by XOMA Royalty Corporation in February 2024 amid strategic alternatives exploration.[2][3][5]
Kinnate emerged from deep expertise in chemistry and structure-based drug design, founded as a precision oncology firm to expand targeted therapies for genetically defined cancers.[1][2][9] Backed by Foresite Capital since its Series A, it assembled a team of oncology veterans with decades of small molecule development experience, appointing leaders like Nima Farzan as CEO and Dr. Richard Williams as Chief Medical Officer, while raising $98 million in Series C financing.[2][7] Pivotal early moments included exiting stealth mode with plans for clinical trials of its RAF inhibitor and building ties with precision medicine centers for genomic insights, though it later pivoted to asset sales and acquisition by XOMA in 2024 to monetize its programs.[3][5][7]
Kinnate rode the precision oncology wave, capitalizing on advances in genomic profiling to target validated kinase drivers in solid tumors where standard therapies fail due to resistance or lack of options.[1][3] Its timing aligned with growing demand for next-generation inhibitors amid rising cancer incidence and limitations of first-line treatments like BRAF inhibitors, influencing the ecosystem by validating pan-RAF and FGFR strategies now advanced by partners like Pierre Fabre and XOMA.[5] Market forces favoring non-dilutive funding and asset sales enabled its evolution, contributing to biotech's shift toward royalty aggregation and collaborative development to accelerate patient access.[2][3]
Post-acquisition by XOMA in February 2024 and exarafenib sale to Pierre Fabre in March 2024, Kinnate's remnants live on through monetized assets, with XOMA poised to out-license programs like FGFR and c-MET inhibitors for royalties.[2][3][5] Trends in AI-driven drug design, deeper genomic insights, and resistance-focused therapies will shape successors, potentially amplifying Kinnate's legacy in kinase targeting. Its influence may evolve via partner advancements, underscoring how precision oncology startups fuel broader ecosystem progress through targeted innovation and strategic exits.[1][3]
